NR ARTP
AU Steinacker,P.; Mollenhauer,B.; Bibl,M.; Cepek,L.; Esselmann,H.; Brechlin,P.; Lewczuk,P.; Poser,S.; Kretzschmar,H.A.; Wiltfang,J.; Trenkwalder,C.; Otto,M.
TI Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases
QU Neuroscience Letters 2004 Nov 3; 370(1): 36-9
PT journal article
AB The diagnosis of neurodegenerative diseases with dementias requires several different test approaches and often remains uncertain. Using a proteomic approach it was shown in nine patients that heart fatty acid binding protein (H-FABP) might be a biomarker for Creutzfeldt-Jakob disease (CJD). The aim of our study was to evaluate whether H-FABP is a biomarker for the differential diagnosis of dementias. Therefore we measured H-FABP in cerebrospinal fluid (CSF) and serum of patients having CJD, dementia with Lewy-bodies (DLB), Alzheimer's disease (AD) and in non-demented control (NDC) patients. H-FABP levels in CSF and serum of CJD patients are increased compared to non-demented controls. Levels of H-FABP were significantly higher in CJD patients compared to AD and DLB in CSF. However, discrimination between CJD and AD was not possible in serum. Interestingly, highest levels of H-FABP were found in serum of DLB patients. Our results suggest that H-FABP might be a useful biomarker for the differentiation between the dementias examined if levels in CSF and serum are determined in parallel.
MH Adult; Aged; Aged, 80 and over; Alzheimer Disease/metabolism; Biological Markers; Carrier Proteins/*blood/*cerebrospinal fluid; Comparative Study; Creutzfeldt-Jakob Syndrome/metabolism; Enzyme-Linked Immunosorbent Assay/methods; Female; Humans; Lewy Body Disease/metabolism; Male; Middle Aged; Myocardium/*metabolism; Neurodegenerative Diseases/*diagnosis/metabolism; Research Support, Non-U.S. Gov't; Statistics, Nonparametric
AD Department of Neurology, University Hospital, Robert-Koch-Str. 40, 37075 Göttingen, Germany.
SP englisch
PO Irland